ClinicalTrials.gg
Active, not recruitingNCT05889598REPROOFUpdated Apr 21, 2026

Resistance Exercise Training to Improve Bone and Articular Cartilage Health in Women

An interventional study of Ballistic Resistance Lower Body Strength Training and Conventional Resistance Lower Body Strength Training in Osteoporosis and Osteoarthritis, sponsored by Loughborough University. Active, not recruiting at 1 site in United Kingdom. Open to female participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Loughborough University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Osteoporosis with a site in United Kingdom — 8 open to participants now, 9 under way, none of them phase 3. Osteoporosis · United Kingdom.

Planned enrollment
18th of 35
110 · median 110
Started
2022
with 1 other
No phase
15 of 57
1 open now
Registered
46th of 57
by date
Lead sponsor
3 of 57
Loughborough University

Among the 57 studies in Osteoporosis with a site in United Kingdom, this one is the 18th largest by planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2022, is one of 15 with no phase, and was the 46th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 57 studies in Osteoporosis with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Osteoporosis with a site in United Kingdom, or all of them as a file.
02

Study summary

Osteoarthritis (degenerative joint disease) and osteoporosis (weak and fragile bones) are common conditions, particularly in women after menopause, and become even more common as we get older. Aging is also associated with sarcopenia, the progressive loss of muscle strength and mass with age. In this three-arm study, the effect of resistance exercise programs with different parameters (such as velocity and load) on various outcomes, including structural changes (bone mineral density, cartilage composition, muscle size), physical function, and biomarkers will be compared.

Read the detailed description

Resistance exercise is effective in improving several risk factors for osteoporosis and osteoarthritis, and is recommended to prevent and manage both conditions, and is also known to counteract sarcopenia. Overall, there is little and inconsistent evidence on the effects of exercise parameters (such as velocity) for the prevention of osteoporosis and osteoarthritis, neither is there a comparison of different velocities on structural parameters and biomarkers. Although osteoporosis and osteoarthritis take a long time to develop, it is possible to look at changes in risk using scans of bones and joints -Dual-Energy X-ray absorptiometry (DXA), peripheral Quantitative Computed Tomography (pQCT), and Magnetic Resonance Imaging (MRI)-, blood and/or urine samples and symptoms.

This study aims to examine the effect of two different resistance exercise interventions (explosive high-velocity vs high-load low-velocity training) on structural changes on bone, articular knee and/or hip cartilage and muscle, as well as biomarkers.

The study will be a 32-week long randomized controlled trial including two exercise groups and one non-exercising control group.

Screening and baseline measurements will then be taken when anonymization is completed. Once participants have completed baseline testing, participants will be randomly assigned to one of the exercise groups or control groups using a block randomization technique. Participants will choose an envelope, prepared in batches of 11, which will contain a note saying either 'ballistic' or 'conventional or 'control' with a ratio of 4:4:3. This is to allow for greater drop-out in the exercise groups. It is not possible to blind the participant or researchers supervising the intervention to the group allocation.

The required exercise program involves two supervised sessions per week at Loughborough University, each lasting no longer than 60 minutes per session. Each session will involve 30-40 minutes of exercise and time to check any symptoms or queries with participants.

The exercises are designed to strengthen major muscle groups of the trunk and lower body, as well as to load bones that are affected by osteoporosis and the knee and hip joints that are commonly affected by osteoarthritis. Each exercise training session will take 30-40 minutes and include some whole-body warm-up and trunk exercises before completing the two main exercises: a hack squat and calf raise. These two main exercises will be done using resistance (weight training) machines in a dedicated exercise facility. Investigators chose a hack squat machine as it exercises many muscle groups and skeletal sites in one exercise, including the spine and lower limb rather than a small area. Additionally, it supports the spine, making it safe and comfortable to use.

The intervention will be personalized to the individual's ability, and loads will steadily increase as the participant improves. The load will be decided according to maximal muscular strength determined by calculation of 1-repetition maximum which will be renewed every month to monitor the progress of their muscle strength and use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.

The two exercise groups will follow the same exercise programmes but using different speeds and weights: The conventional training group will perform the exercises slowly (conventionally), whilst the ballistic group will use lower loads and higher velocity as if trying to jump. Participants will be carefully guided and coached to perform all the exercises correctly and all the exercise training sessions will be supervised by qualified researchers to ensure safety throughout the study.

The control group will be asked to maintain their usual exercise and diet. Follow-up measurements will take place 16 and 32 weeks after the commencement of the exercise programme.

The sample size calculation is based on detecting differences in bone mineral density between each exercise group and the control group. Using an effect size of 0.75 (considered clinically meaningful), alpha of 0.05, and beta errors of 0.95, approximately 28 participants are needed for each group. However, the final sample size should cover a possible number of withdrawals. To allow for a 30% drop-out rate in exercise groups, 110 participants will be recruited for the study.

All data will be reported in the final work; any missing data will be accounted for with reasons for it missing. All measures described in the methodology will be reported, whether results are statistically significant or not. Data from all eligible participants will be included in an intention-to-treat analysis. Multiple imputation will be used for addressing the presence of missing data. The analysis will be repeated in good adherers i.e. those who attended at least 90% of the exercise sessions.

Descriptive statistics will be calculated to give information on mean values and variation (standard deviation) of the cohort. Normal distribution will be analysed using Shapiro-Wilk test. If variance is shown to be homogenous and distribution normal within the population then repeated measures analysis of variance (RM-ANOVA) will detect any significant differences between group (exercise versus control), time (baseline versus post-intervention) or group x time interaction.

03

Conditions studied

  • Osteoporosis
  • Osteoarthritis

Keywords

  • Exercise
  • Explosive high-velocity
  • Bone mineral density
  • Knee joint
  • Neuromuscular
  • Biomarkers
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women between 50-70 years;
  • Experienced last menstrual cycle, hormonal or menopausal hormone replacement therapy at least five years ago;
  • Independent living and able to come into the university;
  • Healthy women: not previously diagnosed with osteoporosis or knee osteoarthritis, other major medical conditions;
  • Able to understand English.

Exclusion criteria

Exclusion Criteria:

  • Any existing symptomatic knee, hip, back injury or any medical conditions or injuries which would affect the ability or safety to perform exercise or influence bone/cartilage, including unstable angina, uncontrolled hypertension, a history of heart failure, and a history of cardiovascular disease and conditions;
  • Taking medication affecting bone/cartilage metabolism;
  • Regular (>once per week on average) participation in resistance training with loading greater than bodyweight or in high impact (impact greater than jogging);
  • Blood pressure exceeding 150/90 mmHg;
  • > 30 kg/m2;
  • to MRI or DXA (e.g. Metallic implants);
  • Osteoporotic (FRAX score according to which the participant would be advised to seek treatment);
  • Fracture within the past year.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Ballistic resistance exercise training

    This arm will perform the exercises in a hack squat machine using low loads and explosive high-velocity (as if trying to jump)

    Other: Ballistic Resistance Lower Body Strength Training

  • Experimental
    Conventional resistance exercise training

    This arm will perform the exercises in a hack squat machine using high-load and low-velocity (conventional training)

    Other: Conventional Resistance Lower Body Strength Training

  • No intervention
    Control

    Continue usual life

Interventions

  • OtherBallistic Resistance Lower Body Strength Training

    The exercise programme involves two supervised sessions per week at University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40%1RM, the ballistic training group will complete eccentric phase hack squat exercise in approximately 3 seconds and the concentric phase as fast as possible with throwing type contractions. If participants can, participants will be allowed to take off in the concentric phase. To maintain high velocity in this group, lower loads will be used compared to the conventional group. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.

  • OtherConventional Resistance Lower Body Strength Training

    The exercise programme involves two supervised sessions per week at Loughborough University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40% of 1RM, the conventional training group will complete eccentric and concentric phases of hack squatting exercises for approximately 3 seconds each, with appropriate breathing techniques. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.

06

What researchers measure

Primary outcomes

  1. Change in Femoral neck bone mineral content from baseline

    (g) measured by DXA

    Time frame: 32nd week

  2. Change in Femoral neck bone mineral density from baseline

    (g/cm\^2) measured by DXA

    Time frame: 32nd week

Secondary outcomes

  1. Bone Mineral Content (Femur)

    Proximal Femur bone will be assessed in "g" by DXA

    Time frame: Baseline, 16th and 32nd weeks

  2. Bone Mineral Density (Femur)

    Proximal femur bone will be assessed (g/cm\^2) by DXA

    Time frame: Baseline, 16th and 32nd weeks

  3. Bone Mineral Content (Spine)

    Lumbar spine bone will be assessed (g) by DXA

    Time frame: Baseline, 16th and 32nd weeks

  4. Bone Mineral Density (Spine)

    Lumbar spine will be assessed (g/cm\^2) by DXA

    Time frame: Baseline, 16th and 32nd weeks

  5. bone mineral content (Forearm)

    Forearm bone will be assessed (g) by DXA

    Time frame: Baseline, 16th and 32nd weeks

  6. bone mineral density (Forearm)

    Forearm bone will be assessed (g/cm\^2) by DXA

    Time frame: Baseline, 16th and 32nd weeks

  7. Bone mineral content (Lower leg)

    Tibia bone will be assessed (g) by DXA

    Time frame: Baseline, 16th and 32nd weeks

  8. bone mineral density (Lower Leg)

    Tibia bone will be assessed (g/cm\^2) by DXA

    Time frame: Baseline, 16th and 32nd weeks

  9. Bone mineral content (Total body)

    Whole body will be assessed (g) by DXA

    Time frame: Baseline, 16th and 32nd weeks

  10. bone mineral density (Total Body)

    Whole body will be assessed (g/cm\^2) by DXA

    Time frame: Baseline, 16th and 32nd weeks

  11. cortical bone subdensity (Forearm)

    Radius bone 4% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  12. total bone density (Forearm)

    Radius bone 4% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  13. trabecular bone density (Forearm)

    Radius bone 4% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  14. bone total density (Forearm)

    Radius bone 66% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  15. cortical bone density (Forearm)

    Radius bone 66% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  16. total bone density (Lower leg)

    Tibia bone 4% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  17. trabecular bone density (Lower leg)

    Tibia bone 4% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  18. cortical bone subdensity (Lower leg)

    Tibia bone 4% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  19. bone total density (Lower leg)

    Tibia bone 38% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  20. cortical bone density (Lower leg)

    Tibia bone 38% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  21. total bone density (66% of Lower leg)

    Tibia bone 66% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  22. cortical density (Lower leg)

    Tibia bone 66% (mg/cm\^3) measured by pQCT

    Time frame: Baseline, 16th and 32nd weeks

  23. T2 relaxation time

    Knee joint cartilage (ms) measured by MRI

    Time frame: Baseline and 32nd week

  24. cartilage thickness

    Knee joint cartilage (mm) measured by MRI

    Time frame: Baseline and 32nd week

  25. Change in bone turnover markers (CTX-1 and PINP) in bodily samples

    Serum/urine will be analysed by ELISA kits

    Time frame: Baseline, 16th and 32nd weeks

  26. Change in serum biomarkers (OPG, DKK1, irisin, IL-6, C2C, PIICP) in serum samples (exploratory, post hoc)

    Additional serum biomarkers, including osteoprotegerin (OPG), dickkopf Wnt signalling pathway inhibitor 1 (DKK1), irisin, interleukin-6 (IL-6), type II collagen cleavage neoepitope (C2C), and procollagen type II C-propeptide (PIICP), were assessed by ELISA kits. These biomarkers were not pre-specified in the original trial registration. Blood samples had been collected during the study period prior to database lock. The decision to include these biomarkers was made after trial completion, and analyses are considered exploratory.

    Time frame: Baseline, 16th and 32nd weeks

  27. Lower limb power

    (W) measured during Hack squat action

    Time frame: Baseline, 16th and 32nd weeks

  28. Lower limb force

    (N) measured during Hack squat action

    Time frame: Baseline, 16th and 32nd weeks

  29. Lower limb velocity

    (m/s) measured during Hack squat action

    Time frame: Baseline, 16th and 32nd weeks

  30. Quadriceps cross-sectional area

    (cm\^2) measured by MRI

    Time frame: Baseline and 32nd week

  31. Triceps surae cross-sectional area

    (cm\^2) measured by pQCT

    Time frame: Baseline and 32nd week

  32. Lower extremity functioning

    (total score in points) using Short Physical Performance Battery. SPPB scores range from zero to 12 possible points. SPPB score of 10 or greater for persons with no mobility disability indicates robustness.

    Time frame: Baseline, 16th and 32nd weeks

  33. Mobility/agility

    The timed Up and Go test is rated on a scale from 1 to 5 where 1 indicates "normal function" and 5 indicates "severely abnormal function"

    Time frame: Baseline, 16th and 32nd weeks

  34. Pain, symptoms, activities of daily living, sport and recreation function, and knee-related quality of life following knee injury

    the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire will be used for that. A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems

    Time frame: Baseline, 16th and 32nd weeks

  35. Pain, stiffness, and physical function of the hip and knee

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score, however there are other methods that have been used to combine scores. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.

    Time frame: Baseline, 16th and 32nd weeks

  36. Physical Activity Level

    Bone-specific Physical Activity Questionnaire (BPAQ). higher scores mean higher physical and better outcomes for the study

    Time frame: Baseline, 16th and 32nd weeks

  37. Physical activity and inactivity level

    International Physical Activity Questionnaire (IPAQ)

    Time frame: Baseline, 16th and 32nd weeks

  38. Daily calcium intake

    (mg) Calcium Questionnaire

    Time frame: Baseline, 16th and 32nd weeks

  39. Static postural sway

    anterior-posterior and medial-lateral mean velocity (cm/s) of the centre of pressure

    Time frame: Baseline, 16th and 32nd weeks

  40. Static postural sway (elliptical area)

    the elliptical area (cm\^2) will be assessed

    Time frame: Baseline, 16th and 32nd weeks

07

Study locations

1 site
08

References and documents

Publications

  • Marques EA, Caliskan O, Brooke-Wavell K, Folland J. Feasibility of ballistic vs conventional resistance training in healthy postmenopausal women: A three-arm parallel randomised controlled trial. Maturitas. 2025 May;196:108246. doi: 10.1016/j.maturitas.2025.108246. Epub 2025 Mar 13. PubMed 40106971 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.

Of 220 non-industry interventional studies with no phase under Osteoporosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 49. This study's planned 57 months is above that.

Counting every sponsor, half of 239 studies reached it within 26 months; a quarter within 9 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
Jun 5, 2023
StartActual
Mar 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 2027
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05889598
Lead sponsor
Loughborough University
Collaborators
Versus Arthritis
Responsible party
Katherine Brooke-Wavell (Senior Lecturer in Human Biology, Loughborough University) — Principal investigator
First posted
Jun 5, 2023
Start date
Mar 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 21, 2026

Study contacts

Katherine Brooke-Wavell, PhD
principal investigator · Loughborough University
Jonathan Folland, PhD
principal investigator · Loughborough University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion